Replication and extension of a model predicting response to psilocybin

This retrospective study (n=183) replicated an earlier model of psilocybin response, which predicts that states of surrender and preoccupation at the time of ingestion are significant variables determining the nature of the experience.

Abstract of Replication and extension of a model predicting response to psilocybin

Background: Recent research demonstrated the potential of psychedelic drugs as treatment for depression and death-related anxiety and as an enhancement for well-being. While generally positive, responses to psychedelic drugs can vary according to traits, setting, and mental state (set) before and during ingestion. Most earlier models explain minimal response variation, primarily related to dosage and trust, but a recent study found that states of surrender and preoccupation at the time of ingestion explained substantial variance in mystical and adverse psilocybin experiences.

Objectives: The current study sought to replicate the previous model, extend the model with additional predictors, and examine the role of mystical experience on positive change.

Method: A hierarchical regression model was created with crowdsourced retrospective data from 183 individuals who had self-administered psilocybin in the past year. Scales explored mental states before, during, and after psilocybin ingestion, relying on open-ended memory prompts at each juncture to trigger recollections. Controlled drug administration was not employed.

Results: This study replicated the previous model, finding a state of surrender before ingestion a key predictor of optimal experience and preoccupation a key predictor of adverse experience. Additional predictors added to the explanatory power for optimal and adverse experience. The model supported the importance of mystical experiences to long-term change.

Conclusion: Mental states of surrender or preoccupation at the time of ingestion explain variance in mystical or adverse psilocybin experiences, and mystical experiences relate to long-term positive change. The capacity to recognize this optimal preparatory mental state may benefit therapeutic use of psilocybin in clinical settings.”

Authors: Suzanne L. Russ, Robin L. Carhart-Harris, Geoffrey Maruyama & M. S. Elliott

Summary of Replication and extension of a model predicting response to psilocybin

Recent research demonstrated that psychedelic drugs can be used to treat depression and death-related anxiety and enhance well-being. However, responses to psychedelic drugs can vary according to traits, setting, and mental state before and during ingestion.

Replication and extension of a model predicting response to psilocybin

Studies have shown positive response for patients with depression, anxiety related to dying, tobacco addiction, and obsessive-compulsive disorder, as well as increased optimism, openness, and personal meaning for healthy individuals. However, responses to psychedelic drugs are not entirely predictable.

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Replication and extension of a model predicting response to psilocybin

https://doi.org/10.1007/s00213-019-05279-z

Paywall | Google Scholar | Backup | 🕊

Cite this paper (APA)

Russ, S. L., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. S. (2019). Replication and extension of a model predicting response to psilocybin. Psychopharmacology236, 3221-3230.

Study details

Compounds studied
Psilocybin

Topics studied
Neuroscience

Study characteristics
Theory Building

Participants
183 Humans

Authors

Authors associated with this publication with profiles on Blossom

Robin Carhart-Harris
Dr. Robin Carhart-Harris is the Founding Director of the Neuroscape Psychedelics Division at UCSF. Previously he led the Psychedelic group at Imperial College London.